Vimarsana
Biggest News Aggregation in the World

Pam Contag News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pam Contag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pam Contag Today - Breaking & Trending Today

Do You Anticipate Attending The Annual JP Morgan Healthcare Conference In Person In January 2022 - Vimarsana News

Do You Anticipate Attending The Annual JP Morgan Healthcare Conference In Person In January 2022

See the answer from Pamela Reilly Contag, Ph.D., the CEO and president of BioEclipse Therapeutics.

Related Topics:
Pam ContagSan Francisco Bay
What Have Been Your Greatest Lessons Learned - Vimarsana News

What Have Been Your Greatest Lessons Learned

What Have Been Your Greatest Lessons Learned? Source: Life Science Leader MY GREATEST EDUCATION CAME NOT IN ACADEMIA, but instead at the hands of investors and colleagues. The ability to see a scientific advance, find the right application, and take it to commercialization is 90% of the work (not the inventing of it). Being a key opinion leader doesn’t mean you are right; you still need data and an open mind. You always need money. People are not always honest about their motivations. If you have questions, ask for the answers and correlate motives and incentives. Newfound authority or inf...

Related Topics:
Pam Contag
BioEclipse to Participate in Biotech Showcase Digital During "J.P. Morgan Week 2021" - Vimarsana News

BioEclipse to Participate in Biotech Showcase Digital During "J.P. Morgan Week 2021"

During Biotech Showcase Digital, registered conference participants will be able to watch a pre-recorded presentation by BioEclipse. Also, Dr. Contag will host virtual one-on-one meetings with registered investors and pharmaceutical and biotechnology companies via the conference's networking and scheduling platform, partneringONE®, to discuss BioEclipse's business and  highlight recent corporate achievements, as well as anticipated milestones in the clinical program for CRX100. BioEclipse has initiated an open-label, Phase 1 dose-escalation study to evaluate the safety, tolerability, and ph...